![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
METABOLISM, TRANSPORT, AND PHARMACOGENOMICS
Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, Rhode Island (D.S., J.Y., D.Y., L.Y., F.A., B.Y.); and CellzDirect, Austin, Texas (E.L.L., C.B.)
Oseltamivir is the main medicine recommended by the World Health Organization in anticipation of next influenza pandemic. This anti-influenza viral agent is an ester prodrug, and the antiviral activity is achieved by its hydrolytic metabolite: oseltamivir carboxylate. In this study, we report that the hydrolytic activation is catalyzed by carboxylesterase human carboxylesterase (HCE) 1. Liver microsomes rapidly hydrolyzed oseltamivir, but no hydrolysis was detected with intestinal microsomes or plasma. The overall rate of the hydrolysis varied among individual liver samples and was correlated well with the level of HCE1. Recombinant HCE1 but not HCE2 hydrolyzed this prodrug and produced similar kinetic parameters as the liver microsomes. Several HCE1 natural variants differed from the wild-type enzyme on the hydrolysis of oseltamivir. In the presence of antiplatelet agent clopidogrel, the hydrolysis of oseltamivir was inhibited by as much as 90% when the equal concentration was assayed. Given the fact that hydrolysis of oseltamivir is required for its therapeutic activity, concurrent use of both drugs would inhibit the activation of oseltamivir, thus making this antiviral agent therapeutically inactive. This is epidemiologically of significance because people who receive oseltamivir and clopidogrel simultaneously may maintain susceptibility to influenza infection or a source of spreading influenza virus if already infected.
Address correspondence to: Dr. Bingfang Yan, Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, Kingston, RI 02881. E-mail: byan{at}uri.edu
This article has been cited by other articles:
|
|
 |
|
  G. Hoffmann, C. Funk, S. Fowler, M. B. Otteneder, A. Breidenbach, C. R. Rayner, T. Chu, and E. P. Prinssen Nonclinical Pharmacokinetics of Oseltamivir and Oseltamivir Carboxylate in the Central Nervous System Antimicrob. Agents Chemother., November 1, 2009; 53(11): 4753 - 4761. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-J. Zhu, D. I. Appel, Y. Jiang, and J. S. Markowitz Age- and Sex-Related Expression and Activity of Carboxylesterase 1 and 2 in Mouse and Human Liver Drug Metab. Dispos., September 1, 2009; 37(9): 1819 - 1825. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Wattanagoon, K. Stepniewska, N. Lindegardh, S. Pukrittayakamee, U. Silachamroon, W. Piyaphanee, T. Singtoroj, W. Hanpithakpong, G. Davies, J. Tarning, et al. Pharmacokinetics of High-Dose Oseltamivir in Healthy Volunteers Antimicrob. Agents Chemother., March 1, 2009; 53(3): 945 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H.-J. Zhu and J. S. Markowitz Activation of the Antiviral Prodrug Oseltamivir Is Impaired by Two Newly Identified Carboxylesterase 1 Variants Drug Metab. Dispos., February 1, 2009; 37(2): 264 - 267. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ose, M. Ito, H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, M. Hosokawa, J. D. Schuetz, and Y. Sugiyama Limited Brain Distribution of [3R,4R,5S]-4-Acetamido-5-amino-3-(1-ethylpropoxy)-1-cyclohexene-1-carboxylate Phosphate (Ro 64-0802), a Pharmacologically Active Form of Oseltamivir, by Active Efflux across the Blood-Brain Barrier Mediated by Organic Anion Transporter 3 (Oat3/Slc22a8) and Multidrug Resistance-Associated Protein 4 (Mrp4/Abcc4) Drug Metab. Dispos., February 1, 2009; 37(2): 315 - 321. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Hata, K. Koseki, K. Yamaguchi, S. Moriya, Y. Suzuki, S. Yingsakmongkon, G. Hirai, M. Sodeoka, M. von Itzstein, and T. Miyagi Limited Inhibitory Effects of Oseltamivir and Zanamivir on Human Sialidases Antimicrob. Agents Chemother., October 1, 2008; 52(10): 3484 - 3491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ose, H. Kusuhara, K. Yamatsugu, M. Kanai, M. Shibasaki, T. Fujita, A. Yamamoto, and Y. Sugiyama P-glycoprotein Restricts the Penetration of Oseltamivir Across the Blood-Brain Barrier Drug Metab. Dispos., February 1, 2008; 36(2): 427 - 434. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Morimoto, M. Nakakariya, Y. Shirasaka, C. Kakinuma, T. Fujita, I. Tamai, and T. Ogihara Oseltamivir (Tamiflu) Efflux Transport at the Blood-Brain Barrier via P-Glycoprotein Drug Metab. Dispos., January 1, 2008; 36(1): 6 - 9. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Yang, D. Shi, D. Yang, X. Song, and B. Yan Interleukin-6 Alters the Cellular Responsiveness to Clopidogrel, Irinotecan, and Oseltamivir by Suppressing the Expression of Carboxylesterases HCE1 and HCE2 Mol. Pharmacol., September 1, 2007; 72(3): 686 - 694. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Fowler, S. M. Lennon, G. Hoffmann, and C. R. Rayner Comments on "Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel" J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 422 - 423. [Full Text] [PDF]
|
|
|
|
|
|
D. Shi, J. Yang, D. Yang, E. L. LeCluyse, C. Black, L. You, F. Akhlaghi, and B. Yan Response to Comments on "Anti-Influenza Prodrug Oseltamivir Is Activated by Carboxylesterase Human Carboxylesterase 1, and the Activation Is Inhibited by Antiplatelet Agent Clopidogrel" J. Pharmacol. Exp. Ther., July 1, 2007; 322(1): 424 - 425. [Full Text] [PDF]
|
|
|
|
|
|
M. Tang, M. Mukundan, J. Yang, N. Charpentier, E. L. LeCluyse, C. Black, D. Yang, D. Shi, and B. Yan Antiplatelet Agents Aspirin and Clopidogrel Are Hydrolyzed by Distinct Carboxylesterases, and Clopidogrel Is Transesterificated in the Presence of Ethyl Alcohol J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1467 - 1476. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
